Regelife is developing next-generation regenerative cell therapies for neurodegenerative diseases, beginning with ALS
Regelife is developing next-generation regenerative cell therapies for neurodegenerative diseases, beginning with ALS. Our approach integrates iPSC-derived neural cells, advanced biomaterials engineering, and AI-enabled design tools to improve cell survival, integration, and therapeutic efficacy. Regelife was founded by scientists and entrepreneurs from Stanford, CU Boulder, and Keio University, including Prof. Kristi Anseth (NAS/NAE/NAM) and Prof. Hideyuki Okano (President of ISSCR). We aim to establish a new paradigm for regenerative medicine by engineering the cellular microenvironment that enables durable neural repair.